INS and Hypoglycemia: Hypoglycemia, and fear of it, negatively affects quality of life and ultimately undermines attempts to improve glycemic control.7,24–26 In the 52-week inTandem1 and 2 trials, sotagliflozin adjunct to insulin significantly decreased the incidence of clinically significant documented hypoglycemia (defined as plasma glucose ≤55 mg/dL in the main trials) relative to placebo, and positively adjudicated severe hypoglycemia occurred in 7.4%, 5.7%, and 4.4% of patients who received placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively, in the pivotal trials.